Evidence map›Paper›PMID 26590659›Full record

ArticleMultiple sclerosis and related disorders2015

Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.

Peter Kosa, Mika Komori, Ryan Waters, Tianxia Wu, Irene Cortese, Joan Ohayon, Kaylan Fenton, Jamie Cherup, Tomas Gedeon, Bibiana Bielekova

2 registry-linked trialsOpen access · greenAbstract readValidation Study
In one paragraph

Article in Multiple sclerosis and related disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01212094 phase1 / phase2terminatednot on this map

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

TypeinterventionalSponsorNational Institute of Neurological Disorders and Stroke (NINDS)Ran2010 to 2015Enrolled44ConditionsMultiple SclerosisArmsRituximab, normal saline
NCT04496830 completednot on this mapstarted 2020, after this paper: background citation

Cerebrospinal Fluid-biomarkers-based Diagnostic and Prognostic Models for Multiple Sclerosis

TypeobservationalSponsorWashington University School of MedicineRan2020 to 2023Enrolled161ConditionsMultiple Sclerosis
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Assessing verbal and spatial memory via smartphone.Frontiers in digital health · 2026
    Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Drug library screen identifies inhibitors of toxic astrogliosis.Multiple sclerosis and related disorders · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Peter KosaNeuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: kosap@mail.nih.gov.
Mika KomoriNeuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: mika.komori2@nih.gov.
Ryan WatersDepartment of Mathematical Sciences, Montana State University, Bozeman, MT, USA. Electronic address: waters@math.montana.edu.
Tianxia WuClinical Neuroscience Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: wuti@mail.nih.gov.
Irene CorteseNeuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: corteseir@ninds.nih.gov.
Joan OhayonNeuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: ohayonj@ninds.nih.gov.
Kaylan FentonNeuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: kaylan.fenton@gmail.com.
Jamie CherupNeuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: jamie.cherup@nih.gov.
Tomas GedeonDepartment of Mathematical Sciences, Montana State University, Bozeman, MT, USA. Electronic address: Gedeon@math.montana.edu.
Bibiana BielekovaNeuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: Bibi.Bielekova@nih.gov.
National Institute of Neurological Disorders and Stroke · USNational Institutes of Health · USMontana State University · US

Funding

Comprehensive multimodal analysis of patients with neuroimmunological diseasesZIANS003055 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI BIELEKOVA, BIBIANA · 2009 to 2018
$9.0M
Impact of hepatocyte lineage life history dynamics on liver homeostasis in the agR01AG040020 · NIA · MONTANA STATE UNIVERSITY - BOZEMAN · PI GEDEON, TOMAS, SCHMIDT, EDWARD E · 2011 to 2015
$1.5M
Intramural NIH HHS Z99 NS999999Intramural NIH HHS ZIA NS003055NIA NIH HHS R01 AG040020
6 · The paper itself

Abstract

Understanding genotype-phenotype relationships or development/validation of biomarkers requires large multicenter cohorts integrated by universal quantification of crucial phenotypical traits, such as central nervous system (CNS) tissue destruction. We hypothesized that mathematical modeling-guided combination of biologically meaningful, semi-quantitative MRI elements characterized by high signal-to-noise ratio will provide such reliable, universal tool for measuring CNS tissue destruction. We retrospectively graded 15 elements in MRI scans performed in 419 untreated subjects with or without neurological diseases, while being blinded to their prospectively acquired clinical scores. We then used 305 subjects for disability-guided mathematical modeling to select and combine MRI elements that had non-redundant contributions to clinical disability, resulting in Combinatorial MRI Scale (COMRIS). We validated our model on the remaining 114 independent subjects. COMRIS requires 5-10 min per scan on average to compute and demonstrates highly significant (p < 0.0001) and validation-consistent Spearman correlation coefficients (0.75, 0.76, and 0.65) for the expanded disability status scale (EDSS), Scripps neurological rating scale (SNRS), and symbol digit modality test (SDMT) measures of neurological disability, respectively. Because COMRIS is not greatly influenced by MRI scanners or protocols and can be computed even in the presence of some motion artifacts, it does not require censoring out patients and it provides comparable results across different cohorts. As such, it represents a broadly available clinical and research tool that can facilitate multicenter research studies and comparative analyses across patient cohorts and research projects.

Indexed as

Disability EvaluationAdultBrainCervical CordCognition DisordersFemaleHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisProspective StudiesSeverity of Illness IndexClinical disabilityMRIMultiple sclerosis

Identifiers

PMID26590659
PMCPMC4656129
OpenAlexW2170127996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.